Ascletis reports positive phase Ib results for oral GLP-1R agonist ASC30 at EASD 2025
The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo
This marks the first of four new U.S. manufacturing sites that Lilly plans to announce this year
Encouraging early detection and breaking the silence around men’s health
ProBioGen will oversee the design, construction, and operation of the 4,600-square-meter GMP manufacturing unit
IND application for EB-003 expected in early 2026
EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
The conference stressed a multi-dimensional approach required to address Antimicrobial Resistance (AMR), focusing on the right approach and strengthening awareness
Designed as an “AI-as-a-Service” platform, VECURA aims to reduce the traditional therapeutic drug discovery timeline of 10–12 years to just a few hours.
This strategic collaboration represents the third clinical trial under Senhwa’s five-year NCI-sponsored cancer research program
Subscribe To Our Newsletter & Stay Updated